Loading…
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $7M | $-221M | $-212M | $-207M | -33.5% | -23.2% | - |
| 2024 | $9M | $-151M | $-293M | $-164M | -161.7% | -35.5% | - |
| 2023 | $14M | $-28M | $-107M | $-8M | -89.1% | - | - |
| 2022 | $0M | $-36M | $-37M | $-29M | -221.6% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 14.02 | 9.04 | 6.94 |
| Operating Expense | 36.90 | 42.75 | 162.50 | 231.05 |
| Operating Income | -36.90 | -28.73 | -153.46 | -224.11 |
| EBITDA | -36.27 | -28 | -151.35 | -221.16 |
| EBIT | -36.90 | -28.73 | -153.46 | -224.11 |
| Pretax Income | -36.90 | -106.81 | -292.96 | -212.39 |
| Net Income | -36.90 | -106.81 | -292.96 | -212.39 |
| Net Income Common Stockholders | -37.52 | -106.81 | -292.96 | -212.39 |
| Total Expenses | 36.90 | 42.75 | 162.50 | 231.05 |
| Interest Expense | 0 | 0 | 0 | 0 |
| Interest Income | 0.01 | 2.72 | 12.84 | 11.72 |
| Research And Development | 23.27 | 23.09 | 129.54 | 187.29 |
| Selling General And Administration | 13.63 | 19.66 | 32.95 | 43.77 |
| Normalized EBITDA | -36.27 | 52.80 | 0.99 | -221.16 |
| Normalized Income | -36.90 | -26 | -140.62 | -212.39 |
| Basic EPS | -3.09 | -5.38 | -5 | -2.43 |
| Diluted EPS | -3.09 | -5.38 | -5 | -2.43 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Total Unusual Items | 0 | -80.80 | -152.34 | 0 |
| Total Unusual Items Excluding Goodwill | 0 | -80.80 | -152.34 | 0 |
| Net Income From Continuing Operation Net Minority Interest | -36.90 | -106.81 | -292.96 | -212.39 |
| Reconciled Depreciation | 0.63 | 0.73 | 2.10 | 2.96 |
| Net Interest Income | 0.01 | 2.72 | 12.84 | 11.72 |
| Net Income From Continuing And Discontinued Operation | -36.90 | -106.81 | -292.96 | -212.39 |
| Total Operating Income As Reported | -36.90 | -109.53 | -305.80 | -224.11 |
| Diluted Average Shares | 12.13 | 19.84 | 58.64 | 87.35 |
| Basic Average Shares | 12.13 | 19.84 | 58.64 | 87.35 |
| Diluted NI Availto Com Stockholders | -37.52 | -106.81 | -292.96 | -212.39 |
| Otherunder Preferred Stock Dividend | 0.62 | 0 | 0 | 0 |
| Net Income Including Noncontrolling Interests | -36.90 | -106.81 | -292.96 | -212.39 |
| Net Income Continuous Operations | -36.90 | -106.81 | -292.96 | -212.39 |
| Other Income Expense | 0 | -80.80 | -152.34 | 0 |
| Other Non Operating Income Expenses | 0 | 0 | 0 | 0 |
| Special Income Charges | 0 | -80.80 | -152.34 | 0 |
| Other Special Charges | 0 | 80.80 | 152.34 | 0 |
| Restructuring And Mergern Acquisition | 0 | 80.80 | 152.34 | 0 |
| Net Non Operating Interest Income Expense | 0.01 | 2.72 | 12.84 | 11.72 |
| Total Other Finance Cost | -0.01 | 0 | 0 | 0 |
| Interest Expense Non Operating | 0 | 0 | 0 | 0 |
| Interest Income Non Operating | 0.01 | 2.72 | 12.84 | 11.72 |
| General And Administrative Expense | 13.63 | 19.66 | 32.95 | 43.77 |
| Other Gand A | 13.63 | 19.66 | 32.95 | 43.77 |
| Operating Revenue | 0 | 14.02 | 9.04 | 6.94 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Immunome, Inc.this co. | IMNM | $2.6B | - | 4.09 | -33.5% | -9.20 |
| Kodiak Sciences Inc. | KOD | $2.7B | - | 17.11 | -146.1% | -11.78 |
| Warby Parker Inc. | WRBY | $2.6B | 2147.00 | 7.15 | 0.4% | 56.61 |
| Tarsus Pharmaceuticals, Inc. | TARS | $2.6B | - | 7.52 | -19.3% | -32.50 |
| Enliven Therapeutics, Inc. | ELVN | $2.6B | - |
| 5.48 |
| -22.6% |
| -17.36 |
| Vera Therapeutics, Inc. | VERA | $2.6B | - | 4.23 | -49.6% | -6.09 |
| Heartflow, Inc. | HTFL | $2.5B | - | 8.38 | -38.8% | -37.97 |
| Celldex Therapeutics, Inc. | CLDX | $2.5B | - | 4.06 | -49.1% | -5.72 |
| Disc Medicine, Inc. | IRON | $2.5B | - | 3.38 | -28.7% | -7.48 |
| Peer Median | - | 2147.00 | 6.32 | -33.8% | -9.63 | |